Santander app and OneCare receive top consumer awards for innovation in Portugal

Héctor Grisi Chief Executive Officer Santander Group
Héctor Grisi Chief Executive Officer - Santander Group
0Comments

The Santander app and OneCare have been named Product of the Year 2026 in Portugal, winning in the Banking App and Health Insurance categories. The awards are based on ratings from over 15,600 Portuguese consumers who evaluated innovation, appeal, and value.

Santander’s app was recognized for its focus on digital transformation and customer experience. The bank now has 1.33 million active digital customers in Portugal, a 5.1% increase from the previous year, making up more than two-thirds of its total customer base. In 2025, daily logins to Netbanco and the bank’s app surpassed 1.1 million, nearly a 10% rise compared to the previous year. Nearly 920,000 customers use the Santander app as their main access point to banking services—an increase of almost 18% year-on-year.

Recent updates to the app include improved MB Way features for faster transactions and cardless withdrawals, full integration with major digital wallets, digital document signing, and real-time request tracking.

Consumer feedback gave the Santander app an overall score of 6.25 out of ten. Sixty-six percent said they would recommend it; seventy-six percent highlighted its visual appeal; sixty-four percent noted its real value.

OneCare is an insurance product from Aegon Santander Portugal that received Product of the Year honors in Health Insurance. It is distinguished by having no age limit for coverage and focusing on preventive medicine with continuous monitoring through a round-the-clock health assistant offering alerts, appointments, answers to questions, and personalized support. Coverage includes consultations in psychology, sleep management, psychotherapy, psychiatry, stress management, and alternative medicines.

OneCare achieved an overall consumer rating of 6.15 points: sixty-eight percent were likely to recommend it; eighty-three percent felt it suited their lifestyle; seventy-nine percent recognized its real value.

The Product of the Year award is now in its twenty-second edition and this year honored seventy-three products across sectors such as finance, health and wellness, technology, and services. The study found that trust remains key at purchase time: seventy-five percent said that seeing a Product of the Year label influences them to try new items.

In addition to these awards, Santander was also named Recommended Brand 2026 by Consumers Trust—a recognition given directly by consumers reflecting positive reputation in Portugal—and ranked first among leading banks with a satisfaction index of 85.5.

The bank stated: “over the past year, Santander has distinguished itself by closely monitoring customer needs and by its ability to transform each interaction into a positive experience.”

Santander Group operates as part of Banco Santander S.A., headquartered in Madrid according to its official website. The group maintains operations across several countries including Portugal and offers services such as auto finance, wealth management and banking solutions. Its approach emphasizes integrity and innovation while supporting community goals.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.